SUNIL SHAH

Sunil Shah is the CEO of the o2h Group which has developed an engine for seeding a pipeline of early stage life science assets through research collaborations, in-licensing, spin-outs & investments. The DNA of o2h is centred around the nurturing of its people, values and culture, it reflects in the way we work with each other, as well as our collaborators and partners. In 2019, Sunil won the UKBAA Angel Investor of the Year Award as well as the OBN Special Recognition Award for his contribution to the life sciences industry in the UK.

Sunil is a Board Director of Cambridge Angels and also is a member of the Advisory Panel of Cancer Research UK (CRUK) which is the UK’s largest cancer research charity. He is also a non-executive director in the Board of Bioindustry Association Ltd. (BIA). He is either Chairman, Director, Board Observer or investor of: Phoremost, Exonate, Opal Oncology, Five Alarm Bio, Somaserve, DeepMatter, Oppilotech, Sentinel, Small Pharma, Arecor, Metrion, Talisman, Stemnovate, Acacia, Privitar and Oxford Drug Design.

Sunil has a degree in Biochemistry and an MBA from Cambridge University.